Disclosure of Interest Declarations - TEAP Medical Technical Options Committee (MTOC) - May 2011

Emmanuel Addo-Yobo Ghana (A5)
Emmanuel Addo-Yobo, member of the Medical Technical Options Committee since 2005, is a full time Senior Specialist Paediatrician and Senior Lecturer in the Department of Child Health, Kwame Nkrumah University Sciences and Technology, and the Komfo Anokye Teaching Hospital, Kumasi, Ghana, with a special interest in paediatric pulmonology. Dr Addo-Yobo is the physician in charge of paediatric asthma in the hospital and has been involved in several research activities on childhood asthma epidemiology in Ghana as Principal or Co-Investigator, some of which have been sponsored partly or fully by pharmaceutical companies. Dr Addo-Yobo has attended an American Academy of Allergy Asthma and Immunology (AAAAI) meeting sponsored by a pharmaceutical company in 1999.  Dr Addo-Yobo does not receive any form of remuneration from any drug companies. Dr Addo-Yobo has given educational lectures to medical personnel on childhood asthma in Ghana, which were sponsored by drug companies in a purely academic capacity. The UNEP’s Ozone Secretariat funds his travels for MTOC meetings. Dr Addo-Yobo’s spouse is a business secretary working with a local financial institution and has no interests in matters before the Protocol.

Paul J. Atkins USA (Non-A5)
Dr Paul Atkins, member of the Medical Technical Options Committee since 1993, is the full time Vice President, Operations of Oriel Therapeutics Inc., a wholly owned subsidiary of Sandoz/Novartis, a publicly traded pharmaceutical company, is based in Research Triangle Park, USA. Oriel Therapeutics Inc. has an interest in the topics of the Montreal Protocol because it is developing dry powder inhalers. Dr Atkins has a proprietary interest in developing alternatives to ODS-based MDIs. Dr Atkins has an extensive background in both MDI and DPI product development and commercialisation and is an internationally recognised expert in this area. Previously Dr Atkins was employed by GlaxoSmithKline, a leading provider of inhaled medicines including CFC-based MDIs, and his spouse is currently a GlaxoSmithKline employee and owns stock in that company. Dr Atkins has worked occasionally as a consultant for both MLF and UNDP on matters related to the Montreal Protocol. Travel to MTOC meetings has been paid by either his employer or out of his personal funds.

Sidney Stuart Braman USA (Non-A5)
Dr Sidney Braman, member of the Medical Technical Options Committee since 2005, is a Professor of Medicine at Brown Medical School in the Division of Pulmonary and Critical Care Medicine at Brown University and the Rhode Island Hospital. These organizations have no direct interest or business relating to the topics of the Montreal Protocol. Dr Braman has no proprietary interest to alternatives or substitutes to ODS, does not own stock in companies producing ODS or alternatives or substitutes to ODS, does not have an interest in the outcome of essential use nominations and does consulting for organizations seeking to phase out ODS but does not consult on these products. He has received research grant support and been a consultant to several pharmaceutical companies relating to research on new drug development. Dr Braman has not received any consultancy fees for work related to or associated with the Montreal Protocol. Dr Braman’s spouse has no interest in matters before the Protocol. Dr Braman does not work as a consultant on matters relates to the Montreal Protocol. Travel to the MTOC meetings is provided by the American Thoracic Society.

Nick Campbell France (Non-A5)
Dr. Nick Campbell has been a member of this Technical Options Committee since 1991. Dr Campbell has spent 20 years working primarily on the ozone layer issue and climate change. Dr Campbell works for ARKEMA SA, based in Paris, as the Environment Manager for the Fluorinated Products Division. ARKEMA SA is a producer of CFCs, HCFCs and HFCs. ARKEMA SA supports his participation and travel on MTOC. Dr Campbell has stock options in ARKEMA SA. He is Chairman of the European Fluorocarbon Technical Committee (EFCTC) that represents the producers of fluorocarbons in the European Union and the European Chemical Industry Council (CEFIC) Working Party on Climate Change. Dr Campbell is also the Chairman of the International Chamber of Commerce (ICC) Working Party on Climate Change and the Chairman of the BusinessEurope Climate Change Working group, representing European Union Employers’ federations. Dr Campbell has been a member of the World Bank’s Ozone Operations Resource Group. Nick was a Coordinating Lead Author for the IPCC/TEAP joint Report on HFCs and PFCs (April, 2005). Dr Campbell was awarded a 1997 United States EPA Stratospheric Ozone Protection Award for his role in the phase-out of ODS.

Hisbello Campos Brazil (A5)
Dr. Hisbello S. Campos, member of the Medical Technical Options Committee since 1997, is a medical physician (pulmonologist) who works for Brazil´s Ministry of Health at Centro de Referencia Prof. Helio Fraga,  Instituto Fernandes Figueira, FIOCRUZ (IFF/FIOCRUZ). Dr Campos is a full time physician at the Centro de Referencia Prof. Helio Fraga IFF/FIOCRUZ and gives medical consultations at his private office. The Centro de Referencia Prof. Helio Fraga IFF/FIOCRUZ is a national institute for child care, being reference for several pulmonary and respiratory diseases. In this institution, Dr. Hisbello Campos is responsible for teaching and research, and coordinates the severe asthma outpatient unit. The Centro de Referencia Prof. Helio Fraga IFF/FIOCRUZ has an interest in the topics of the Montreal Protocol because it is the government department responsible for proposing guidelines for respiratory diseases control. Dr Campos has no proprietary interest in alternatives or substitutes to ODS, does not own stock in companies producing ODS or alternatives or substitutes to ODS, does not have an interest in the outcome of essential use nominations, and does not consult for organizations seeking to phase out ODS. Dr. Campos gives educational lectures for physicians or goes to international medical meetings (American Thoracic Society, European Respiratory Society or World Asthma Meeting, for example), sponsored by pharmaceutical companies, some of which have continued to produce CFC MDIs, and some of which have sought to accelerate phase out of CFC MDIs. Dr Campos’s spouse has no interest in matters before the Protocol. Dr Campos works occasionally as a consultant to the Brazilian Government on matters related to the Montreal Protocol. Dr. Hisbello Campos’ spouse has no interest in matters before the Protocol. UNEP’s Ozone Secretariat pays travel to MTOC meetings.

Jorge Osvaldo Cáneva Argentina (A5)
Dr. Jorge Osvaldo Cáneva, member of the Medical Technical Options Committee since 2007, is the Chief of the Pulmonary Section at of the University Hospital of the Favaloro Foundation (Buenos Aires, Argentina) since it was established in 1992, and Professor of the University School of Medicine at the same institution. Currently Dr. Cáneva states as Ex-President of the Argentine Association of Respiratory Medicine (Asociación Argentina de Medicina Respiratoria), main association in pulmonary medicine in Argentina. He was Governor of the American College of Chest Physician in Argentina between 2006-2009. He is the coordinator of the Bi-National Programme for pulmonary and cardiopulmonary transplantation between Argentina and Uruguay. He has been involved in severe respiratory diseases, pulmonary vascular diseases and lung transplantation programmes. During 2003 and 2004 Dr Cáneva has been involved in consultation for AstraZeneca Argentina about dry powder inhalers. Between 1993 and 2008, Dr Cáneva has served as independent consultant on long-term oxygen therapy for Air Liquide Argentina. Furthermore, he serves as independent consultant about inhaled (nebulized) therapy for the treatment of pulmonary vascular diseases. Dr Cáneva does not own stock in companies producing ODS or alternatives or substitutes to ODS; he does not consult for organizations seeking to phase out ODS. Dr Cáneva’s spouse has no relationship with any pharmaceutical company. He does not receive any honorarium or grant from the government, national or international non- for-profit organization. UNEP’s Ozone Secretariat pays travel to MTOC meetings.

Christer Carling Sweden (Non-A5)
Christer Carling, member of the Medical Technical Options Committee since 1993, is retired from a position as Director Global Licensing at the pharmaceutical company AstraZeneca, which is developing and supplies inhalable drugs such as DPIs and MDIs for the treatment of asthma and COPD. Mr Carling is at present an independent consultant in the pharmaceutical area. His on-going consultancy activities do not involve services to any organization with an interest in the topics of the Montreal Protocol. Mr Carling is a minor shareholder in AstraZeneca but has no proprietary interest in substitutes to ODS, does not own stock in companies producing ODS or substitutes to ODS, does not have an interest in the outcome of essential use nominations, and does not consult for organizations seeking to phase out ODS. Since 2009 Mr Carling has participated annually in regional UNEP seminars in South Asia, presenting on aspects of the Essential Use Nomination (EUN) process and assisting individual Article 5 countries in the South Asia region in their EUN preparations. As a consequence, during the 2011 MTOC meeting, Mr Carling abstained from participation in decisions regarding the EUNs from Bangladesh, China, and Pakistan. Mr Carling also participated in the TEAP/MTOC mission on CFC MDI transition in the Russian Federation in February 2010. His spouse has, until 2010, been an AstraZeneca employee but has no interest in matters before the Protocol. The Ozone Secretariat provided reimbursement for Mr Carling’s travel associated with the TEAP/MTOC mission to the Russian Federation from funds granted to the Secretariat for this purpose by the Governments of Finland and Sweden and by pharmaceutical companies, JSC Moschimpharmpreparaty and JSC Altayvitamin, in the Russian Federation. Mr Carling’s travel to the 2011 MTOC meeting is sponsored by the Government of Sweden.

Gui-liang Chen China (A5)
Dr Gui-liang Chen, member of the Medical Technical Options Committee since 2008, is a chief pharmacist, and a full time deputy director at the Shanghai Institute for Food and Drug Control (SIFDC). The SIFDC has an interest in the topics of the Montreal Protocol because it is an official institute for drug quality control in China. Gui-liang Chen has been engaged in assessing the safety, efficacy and quality of inhalation products since 2002. Gui-liang Chen has no proprietary interest in alternatives or substitutes to ODSs, does not own stock in companies producing ODS or alternatives or substitutes to ODSs, and does not consult for organizations seeking to phase-out ODSs. Gui-liang Chen’s spouse works at a local hospital in Shanghai, and has no interest in matters before the Protocol. Dr Chen works occasionally as a consultant to the China Government on matters related to the Montreal Protocol. Travel to MTOC meetings is paid by UNEP’s Ozone Secretariat.

Davide Dalle Fusine Italy (Non-A5)
Davide Dalle Fusine is a new member of the Medical Technical Options Committee as of 2011. Mr. Dalle Fusine, a chemist, is Director of International Commercial Operations at Chiesi Farmaceutici, Italy. Mr. Dalle Fusine began his career working in manufacturing operations for pharmaceutical products, including the industrial development of a wide range of formulations including products for inhalation. He has devoted the second half of his career to the Business Development and Business Management of foreign and emerging markets such as East Europe, Latin America, Asian Pacific and Middle East and North Africa regions. Chiesi Farmaceutici has an interest in the topics of Montreal Protocol as it is engaged in the development, manufacturing and marketing of MDIs and DPIs in international markets. The participation costs of Mr. Dalle Fusine on MTOC are fully borne by Chiesi Farmaceutici, Italy.

Charles Hancock USA (Non-A5)
Charles O. Hancock, member of the Medical Technical Options Committee since 1991, is a private medical device sterilization consultant with Charles O. Hancock Associates, Inc. Mr Hancock has an interest in the topics of the Montreal Protocol because he is actively engaged in the safe and effective delivery of sterilization processes for medical devices in healthcare applications. Mr Hancock has proprietary interest in alternatives or substitutes to ODS, owns stock in a company producing alternatives or substitutes to ODS, does not have an interest in the outcome of essential use nominations, and does provide consulting for organizations seeking to phase out ODS. Mr Hancock’s spouse has no interest in matters before the Protocol. Mr Hancock works frequently as a consultant to governments, companies, and healthcare institutions on matters related to the Montreal Protocol. Travel to MTOC meetings is paid by Mr Hancock.

Eamonn Hoxey UK (Non-A5)
Dr. Eamonn Hoxey, member of the Medical Technical Options Committee since 1996, is Vice President for Regulatory Compliance for Johnson & Johnson Medical Devices and Diagnostics companies. Dr Hoxey is a full time employee based in the UK. Johnson & Johnson has an interest in the topics of the Montreal Protocol as a manufacturer of healthcare products, including sterile products, and utilize in-house and external sterilization facilities that do not employ ODS. Dr Hoxey is chairman of the International standards committee on sterilization of healthcare products. Dr Hoxey has no stock in companies involved in ODS, with the possible exception of stock held in portfolio accounts where he has no control over purchase or sale. Dr Hoxey’s partner has no interest in matters before the Protocol. Johnson & Johnson makes in-kind contributions of wage and miscellaneous expenses.

Javaid Khan Pakistan (A5)
Prof. Javaid Khan, member of the Medical Technical Options Committee since 1999, is a Professor and Head Section of Pulmonology and Critical Care Medicine at the Aga Khan University, Karachi Pakistan. Dr Khan has attended Chest Conferences, such as ATS, sponsored by pharmaceutical companies. Dr Khan takes an active role in educating doctors and the public on asthma and COPD. Pharmaceutical companies have sponsored some of these meetings. Dr Khan has received honorarium from Pfizer Company for his lectures to doctors on smoking cessation in 2007 in Pakistan. He is also a member of the Global Initiative for Asthma (GINA) assembly and GOLD (Global Alliance of Obstructive Lung Disease National leader from Pakistan. In 2009 Prof. Javaid Khan responded to a request made by the Ministry of Environment Pakistan to provide information about the availability and cost of inhalers for Pakistan's essential use nomination.  He has no interest in the outcome of Pakistan's essential use nomination other than a physician's interest in ensuring MDIs remain available to patients at affordable prices. UNEP funds Dr Khan’s travel expenses to attend the meetings of MTOC.

Katharine Knobil USA (Non-A5)
Katharine Knobil, M.D., member of the Medical Technical Options Committee since 2011, is the Vice President of China Medicines Development, Research and Development at GlaxoSmithKline. GlaxoSmithKline has an interest in the topics of Montreal Protocol, as it is engaged in development, manufacturing and marketing of MDIs and DPIs in international markets, and an interest in the outcome of the China essential use nomination for 2012. As a consequence, during the 2011 MTOC meeting, Dr. Knobil abstained from participation in decision-making regarding China’s essential use nomination. With many years of respiratory clinical development experience, Dr. Knobil has been involved in the development of medicines for the treatment of respiratory diseases, including medicines delivered via MDI and DPI.  Dr. Knobil has a proprietary interest in developing alternatives to ODS-based MDIs. Dr. Knobil's spouse has no interest in matters before the Protocol. Travel expenses for participation in the MTOC are provided by GlaxoSmithKline.

Suzanne Leung USA (Non-A5)
Suzanne Leung, Ph.D., Regulatory Affairs Manager for 3M Sterilization Assurance Products, is a member of the Medical Technical Options Committee since 2010.  3M has an interest in the topics of the Montreal Protocol, as it is involved in development, manufacturing and supply of both sterilization products and metered dose inhalers to global markets.  Dr. Leung is a member of American standards committees for sterilization of healthcare products and various industry groups for sterilization.  She has laboratory experience with the use of ODS and ODS-alternatives in sterilants, topical aerosols and metered dose inhalers.  Dr. Leung and her spouse hold stock in companies involved in the manufacture of products containing ODS and ODS alternatives.  3M makes in-kind contributions of wage and miscellaneous expenses for Dr. Leung’s participation on MTOC. 

Nasser Mazhari Motlagh Iran (A5)
Dr. Nasser Mazhari Motlagh, member of the Medical Technical Option Committee since 2007, is a pharmacist at the Sina Darou Laboratories Company plc. Nasser Mazhari is a full time Quality Assurance Manager and Executive Deputy at the Sina Darou pharmaceutical and hygienic manufacturing plant, Tehran. Nasser Mazhari holds a doctorate in pharmacy and has more than 40 years experience in pharmaceutical industry (manufacturing), including more than 13 years in MDIs. The Sina Darou Laboratories Co. plc., a former manufacturer of CFC MDIs, currently has no interest in the topics of the Montreal Protocol as it now manufactures HFC MDIs, does not export MDIs nor compete with any other companies producing CFC MDIs. Nasser Mazhari has consulted and worked for Sina Darou in phasing out CFCs. Nasser Mazhari has no proprietary interest in alternatives or substitutes to ODSs, does not owns stock in companies producing ODS or alternatives or substitutes to ODS. Nasser Mazhari is a minor stockholder of Sina Darou Labs Co. plc. Nasser Mazhari's spouse has no interest in matters before the Protocol. Travel expenses of Nasser Mazhari to MTOC meetings are paid by UNEP’s Ozone Secretariat.

Gerald McDonnell United Kingdom (Non-A5)
Dr. Gerald McDonnell, member of the Medical Technical Options Committee since 2010, is Vice President for Research and Technical Affairs for STERIS Corporation, as supplier of infection and contamination prevention/control and surgical support products and services. Dr McDonnell is a full time employee based in the UK. STERIS has an interest in the topics of the Montreal Protocol as a manufacturer and service provider of cleaning, disinfection and sterilization technologies. Dr. McDonnell is an active participant and country representative for British, European and International standards committees on sterilization of healthcare products. Dr McDonnell is a minor stockholder of STERIS, which provides sterilization products and services discussed in this report. Dr McDonnell’s partner or family has no interest in matters before the Protocol. STERIS makes in-kind contributions of wage and miscellaneous expenses for Dr. McDonnell to participate on MTOC.

Hideo Mori Japan (Non-A5)
Hideo Mori, member of the Medical Technical Options Committee since 1999, retired from the Regulatory Department at Otsuka Pharmaceutical, based in Tokushima Japan, and now works as a consultant of the same company. Otsuka Pharmaceutical accomplished the phase-out of CFC MDIs and manufactures CFC-free MDIs and DPIs. Mr Mori is the former chair and an adviser of the CFC Committee of the Federation of Pharmaceutical Manufacturers’ Association of Japan, which was organized to accomplish the phase-out of CFCs in MDIs and smooth transition to the alternatives. Mr. Mori does not own stocks in companies producing ODS, or alternatives or substitutes to ODS, does not have an interest in the outcome of essential use nominations. Since 2008, Mr Mori participated in regional UNEP workshops in South Asia, presenting on aspects of the Essential Use Nomination (EUN) process and assisting individual Article 5 countries in the South Asia region in their EUN preparations. As a consequence, during the 2011 MTOC nomination discussions, Mr Mori abstained from participation in decisions regarding the EUNs from Bangladesh, China, and Pakistan. The CFC Committee provides a grant for Mr Mori’s travel to attend MTOC and MOP/OEWG meetings.

Tunde Otulana USA (Non-A5)
Dr Tunde Otulana, member of the Medical Technical Options Committee since 1995, is Senior Vice President and Chief Medical Officer at Aerovance Inc. Dr Otulana is a full time executive at Aerovance in Berkeley, California. Aerovance has an interest in the topics of the Montreal Protocol because it operates in the general field of respiratory diseases. Dr Otulana has no proprietary interest in alternatives or substitutes to ODS, does not own stock in companies producing ODS or alternatives or substitutes to ODS, does not have an interest in the outcome of essential use nomination, and does no consulting for organizations seeking to phase out ODS. Dr Otulana’s wife has no interest in matters before the Protocol. Dr Otulana’s travel to MTOC meetings is paid by Aerovance. 

Jose Pons Pons (co-chair) Venezuela (A5)
Jose Pons, who is President of Spray Química C.A, was co-chair of the Technology and Economic Assessment Panel since 2004 until 2010 and is co-chair of the Medical Technical Options Committee since 1991. Spray Química had an interest in the topics of the Montreal Protocol because it used ODS in some of its aerosol products for industrial maintenance. Mr. Pons is President of the Venezuelan Chamber of Aerosols, CAVEA and has worked in ozone layer protection since 1989. He has participated in several TEAP Task Forces and on the Steering Committee to the “IPCC/TEAP Special Report Safeguarding the Ozone Layer and the Global Climate System: Issues Related to Hydrofluorocarbons and Perfluorocarbons”. Mr Pons has no proprietary interest in alternatives or substitutes to ODS, does not own stock in companies producing ODS or alternatives or substitutes to ODS, does not have an interest in the outcome of essential use nominations, and does not consult for organisations seeking to phase out ODS. Mr Pons’s spouse has no interest in matters before the Protocol; she is also a manager/engineer at Spray Química. Mr Pons has worked occasionally as a project reviewer for the MLF and implementing agencies on matters related to the Montreal Protocol. Travel related to participation in the TEAP and MTOC, and relevant Protocol meetings, are paid by UNEP’s Ozone Secretariat. Spray Química makes in-kind contributions of wage, and miscellaneous and communication expenses.

John Pritchard UK (Non-A5)
Dr. John Pritchard, member of the Medical Technical Options Committee since 2006, is Chief Technology Officer in the Respiratory Drug Delivery Group of Philips Home Healthcare Solutions since January 2011, having previously held a variety of roles within AstraZeneca, 3M, GlaxoSmithKline and AEA Technology (formerly UK Atomic Energy Authority). Dr. Pritchard has published extensively in the field of aerosol science and is a past President of The Aerosol Society, a past member of the UK Government Committee on the Medical Effects of Airborne Pollutants, has represented AstraZeneca on the Board of the International Pharmaceutical Aerosols Consortium (a group of companies that manufacture medicines for the treatment of respiratory illnesses) and has served as editor on a number of journals. Philips has an interest in the topics of Montreal Protocol, as it is engaged in the diagnosis, development, manufacturing and supply of products to treat respiratory illness across international markets. Dr. Pritchard is also a minor shareholder in a range of companies, including AstraZeneca and GlaxoSmithKline that manufactured CFC MDIs and now offer HFC MDIs and DPIs as alternatives. Travel expenses for participation in MTOC are provided by Philips.

Rabbur Reza Bangladesh (A5)
Rabbur Reza, member of the Medical Technical Option Committee since 2009, is the full time Chief Operating Officer at Beximco Pharmaceuticals Ltd, Bangladesh. Beximco Pharmaceuticals is the largest MDI manufacturer in Bangladesh and has an interest in the topics of Montreal Protocol, as it is engaged in development, manufacturing and marketing of MDIs in local and international markets. He has no proprietary interest in alternatives or substitutes to ODS, does not own stock in companies producing ODS or alternatives or substitutes to ODS; however, his employer has an interest in the outcome of the Bangladesh essential use nomination made for 2012. As a consequence, during the 2011 MTOC meeting Mr. Reza abstained from participation in decision-making regarding Bangladesh’s essential use nomination. Rabbur Reza has considerable experience in MDI product and business development and does consulting and working for Beximco Pharmaceuticals to phase out CFC-based MDIs. Rabbur Reza’s spouse is a medical practitioner and has no interest in matters before the Protocol. UNEP’s Ozone Secretariat funds his travel expenses for participation on MTOC.

Raj Bright Singh India (A5)
Dr Raj B Singh, member of the Medical Technical Options Committee since 2005, is a clinical respiratory physician engaged in private practice in Chennai, South India. Nearly 90 per cent of his work concerns clinical respiratory medicine, with out-patients at the Chest Centre and in-patient facilities at the Apollo Hospital, Chennai where he is a senior consultant. He is the founder of the Chest Foundation of India and its Managing Trustee. Dr Singh was a member of the Executive Committee of the Global Initiative for Asthma (GINA) from 2003 to 2007. He uses a portfolio management service that may buy shares of pharmaceutical companies from time to time. Attendance of the European Respiratory Society 2009 was funded by CIPLA. He received Rs 13500 (US$ 280) from GSK and Rs 6000 (US$130) from Astra Zeneca in 2009 for lectures, and expects to receive Rs 10,000 (US$ 225) from each of MSD and Novartis for lectures given in 2011. UNEP’s Ozone Secretariat funds his travel expenses for participation on MTOC.

Roland Stechert Germany (Non-A5)
Dr. Roland Stechert, member of the Medical Technical Options Committee since 2000, is the Head of Clinical Trial Services and Regional Medical Advisor Cardio-Vascular in the Medical Department of Boehringer Ingelheim, Germany. Boehringer Ingelheim has an interest in the topics of Montreal Protocol, as it is engaged in development, manufacturing and marketing of MDIs and DPIs in international markets. His employer has an interest in the outcome of the China essential use nomination made for 2012. As a consequence, during the 2011 MTOC meeting Dr. Stechert abstained from participation in decision-making regarding China’s essential use nomination. As an expert of respiratory research, Dr. Stechert was involved in the development of CFC-free MDIs with Boehringer Ingelheim. Dr Stechert headed the German regional International Pharmaceutical Aerosol Consortium (IPAC) Group until 2002. Since he took over his role from 2003-2010 as a medical director in Switzerland, and more lately his role in Germany, Dr Stechert has not been a member of IPAC. Participation costs are all borne by the affiliate in Germany.

Helen Tope (co-chair) Australia (Non-A5)
Helen Tope, co-chair Medical Technical Options Committee since 1995, is Principal Consultant of Energy International Australia and also Director of Planet Futures with whom she is an independent consultant providing strategic, policy and technical advice and facilitation services to government, industry and other non-governmental organisations on climate change, ozone-depleting substances, and other environmental issues. Dr Tope’s business has an interest in the topics of the Montreal Protocol because her potential clients are also interested in these topics. Dr Tope has no proprietary interest in alternatives or substitutes to ODS, does not own stock in companies producing ODS or alternatives or substitutes to ODS, does not have an interest in the outcome of essential use nominations, and consults for organisations that support the Montreal Protocol in phasing out ODS. Dr Tope’s spouse, Mr. Michael Atkinson, is also her business partner, whose business has an interest in the topics of the Montreal Protocol. During 2010, TEAP Co-Chair Dr. Stephen O. Andersen, Mr. Atkinson and Dr. Tope were unpaid advisors to a UNEP project on investment metrics for identifying technology that minimizes climate and other impacts when replacing ozone-depleting and high-GWP substances. In 2011 Dr Tope’s funding for travel to MTOC, TEAP and other meetings will be provided from several sources. The Ozone Secretariat provides a grant for Dr Tope’s travel and accommodation to attend the MTOC meeting from funds granted to the Secretariat unconditionally by the International Pharmaceutical Aerosol Consortium (IPAC), which is a non-profit corporation. The Australian Government’s Department of Sustainability, Environment, Water, Population and Communities (DSEWPC) is providing funds for Dr. Tope’s travel and accommodation to attend the TEAP meeting.  Funding for the cost of travel and accommodation for Dr Tope’s attendance of the OEWG-31 and the MOP-23 are yet to be confirmed. She makes considerable in-kind contributions of her time without compensation.

Ping Wang China (A5)
Dr Wang Ping, MD, a member of the Medical Technical Options Committee since 2008, is the deputy secretary general of Chinese Pharmacopoeia Commission. Dr Wang Ping is a full time Chief pharmacist at the Chinese Pharmacopoeia Commission, Beijing, P.R. China. The Chinese Pharmacopoeia Commission has an interest in the topic of the Montreal Protocol because it making the standards for all the drugs sold in China, including for CFC MDIs for asthma and COPD. Dr Wang Ping has no proprietary interest in alternatives or substitutes to ODS, does not own stock in companies producing ODS or substitutes to ODS, does not have a financial interest in the outcome of essential use nominations, and does not consult for organizations seeking to phase out ODS. Dr Wang Ping's spouse also has no financial or other interest in matters before to the Montreal Protocol. UNEP’s Ozone Secretariat funds his travel expenses for participation on MTOC.

Adam Wanner USA (Non-A5)
Dr. Adam Wanner, member of the Medical Technical Options Committee since 1995 has had a long-standing interest in aerosol therapy for obstructive lung disease, both as a researcher and clinician. On occasion, the American Lung Association and American Thoracic Society have sponsored his travel to MTOC meetings. Dr Wanner has received academic grants (unrelated to the CFC phase-out) from several pharmaceutical companies. Dr Wanner and his spouse have no financial interests relevant to his work on MTOC.

Kristine Whorlow Australia (Non-A5)
Kristine Whorlow, member of the Medical Technical Options Committee since 2006, is the CEO of the National Asthma Council Australia. The National Asthma Council Australia has an interest in the Montreal Protocol because it led the phase-out of CFC-containing inhalers for respiratory disease in partnership with the Australian Department of the Environment in Australia. Ms Whorlow has no proprietary interest in alternatives or substitutes to ODS, does not own stock in companies producing ODS or alternatives or substitutes to ODS, does not have an interest in the outcome of essential use nominations. The National Asthma Council Australia receives funding from some pharmaceutical companies for projects in Australia and Asia Pacific not associated with the phase-out of ODS. Following the 2010 MTOC meeting in Shanghai, Ms Whorlow spoke at the Inhalation Drug Delivery Conference in Yangzhou at the invitation of the Shanghai Institute of Pharmaceutical Industry, The National Asthma Council Australia funds Ms Whorlow’s travel to MTOC meetings. Ms Whorlow’s partner has no interest in matters before the Protocol.

Ashley Woodcock (co-chair) UK (Non-A5)
Prof. Ashley Woodcock, co-chair of the Medical Technical Options Committee and Member of the Technology and Economic Assessment Panel, is a Professor of Respiratory Medicine at the University of Manchester, and Respiratory Physician at the University Hospital of South Manchester, United Kingdom. The Hospital and University have no direct interest in the topics of the Montreal Protocol. Prof. Woodcock has no proprietary interest in alternatives or substitutes to ODS, does not own stock in companies producing ODS or alternatives or substitutes to ODS, does not have an interest in the outcome of essential use nominations. Prof. Woodcock carries out unrelated consulting and educational lectures for pharmaceutical companies, all of which have phased out CFC MDIs. He regularly advises companies on study design for new drugs, some of which have been ODS replacements. Prof. Woodcock’s spouse has no interest in matters before the Protocol. Prof. Woodcock does not work as a consultant to the UN, UNEP, MLF or Implementing Agencies. In the past, he has responded to requests for technical information on CFC MDI phase-out from the European Community and the United Kingdom Government. Travel and subsistence for meetings of TEAP, MTOC, OEWG, MOP meetings is paid from Hospital and University funds, and Prof. Woodcock’s employers allows leave of absence.

You Yizhong China (A5)
Dr. You Yizhong, member of the Medical Technical Options Committee since 1997, is a chief pharmacist and associate chief physician. Dr You has been devoted to promoting the wide use of inhalation therapy in China for 35 years and to phasing out CFCs from aerosols for 15 years. Dr You developed some anti-asthmatic drugs including MDI, tablet, syrup and suppository. Dr. You organized 14 aerosol conferences, seminars on the phase-out of CFCs from aerosols in China, including 4 special conferences on the phase-out of CFCs from pharmaceutical aerosols and MDIs. Dr You receives his salary from The First People’s Hospital of Changzhou and has no interest or economic relationship with pharmaceutical companies, and does not receive any fees for work associated with MTOC. UNEP's Ozone Secretariat funds his travel expenses to attend MTOC meetings.